说明:双击或选中下面任意单词,将显示该词的音标、读音、翻译等;选中中文或多个词,将显示翻译。
您的位置:首页 -> 词典 -> 利妥昔单抗
1)  Rituximab
利妥昔单抗
1.
Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin s lymphoma;
利妥昔单抗对于非霍奇金淋巴瘤的治疗及其药物经济学
2.
Rituximab in Combination with CHOP Scheme for Non-Hodgkin s Lymphoma: Evaluation of Clinical Efficacy;
利妥昔单抗联合CHOP方案治疗NHL的临床疗效评价
3.
Expression of CD16ζ in NK Cells of B-cell Non-Hodgkin s Lymphoma Patients and In Vitro Killing Effect of Rituximab Combined Lymphokine-activated Killer Cells on B-NHL Cells;
B-NHL患者NK细胞中CD16ζ表达及利妥昔单抗与LAK细胞的联合抗瘤作用
2)  rituximab
利妥昔单克隆抗体
1.
In order to evaluate the effecicney of rituximab combined with fludarabine,cyclophosphamide and rituximab(FCR) regimen for chronic lymphocytic leukemia(CLL).
为了探讨利妥昔单克隆抗体联合氟达拉滨及环磷酰胺(FCR方案)治疗慢性淋巴细胞白血病(CLL)的疗效,采用FCR方案(2-6个疗程)治疗5例CLL患者,其中2例初治、3例复治。
2.
The aim of this study was to compare the efficacy of rituximab plus CHOP regimen and CHOP regimen on newly diagnosed patients with diffuse large B-cell lymphoma(DLBCL),and analyze their toxicities.
为比较利妥昔单克隆抗体联合标准CHOP方案与标准CHOP方案治疗初治CD20阳性的弥漫慢大B细胞淋巴瘤(DLBCL)患者的疗效和安全性,采用同期(2003年7月至2006年12月)非随机对照的前瞻性研究方法,将69例在我院住院的初治DLBCL患者分为R-CHOP组和CHOP组,其中CHOP组36例,R-CHOP组33例,比较两组的完全缓解率、生存期及不良反应情况。
3)  Cetuximab
西妥昔单抗
1.
Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck;
西妥昔单抗联合化疗或放疗治疗晚期头颈鳞癌的疗效评价(英文)
2.
Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402;
西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用
3.
Clinical observation of combination chemotherapy for metastatic colorectal cancer with Cetuximab;
西妥昔单抗联合化疗治疗转移性结直肠癌的临床观察
4)  Cetuximab(C225)
西妥昔单抗(C225)
5)  infliximab
英利昔单抗
1.
Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomized,double blind,controlled trial;
英利昔单抗联合甲氨蝶呤治疗类风湿关节炎的随机双盲临床研究
2.
Methods: A retrospective analysis of incidence rate of adverse events(AE),serious adverse events(SAE) and laboratory test abnormal outcomes was conducted for patients with AS who were treated with infliximab and etanercept according to WHOART systematic classification by World Health Organization.
方法:对应用英利昔单抗(infliximab)和依那西普(etanercept)治疗期间及随访过程中AS患者所发生的全部不良事件、严重不良事件、实验室检查等进行总结分析,根据世界卫生组织不良反应术语命名(WHOART)系统进行分类,观察不良事件的发生情况。
3.
OBJECTIVE:To evaluate the efficacy and the safety of infliximab for the treatment of the diseases of digestive system.
目的:评价英利昔单抗在消化系统相关疾病治疗中的疗效和安全性。
6)  Basiliximab
巴利昔单抗
1.
Application of basiliximab in prevention of acute allograft rejection in kidney transplantation recipients;
巴利昔单抗在预防肾移植后排斥反应中的应用
2.
Influence of basiliximab and on recipients interleukin-2 and soluble interleukin-2 receptor after renal transplantation;
巴利昔单抗对肾移植受者白细胞介素2和可溶性白介素2受体的影响
3.
Meta-analysis of the effect of basiliximab on renal graft rejection and survival
巴利昔单抗对肾移植排斥反应及移植物存活影响的Meta分析
补充资料:奥昔克利平
分子式:
CAS号:

性质:又名奥昔克利平。本品盐酸盐为白色结晶性粉末,无臭,熔点231~232℃,234℃时分解,溶于水、甲醇、乙醇、氯仿、乙醚。(R)-型盐酸盐,熔点234~236℃(分解):(S)-型盐酸盐,熔点229~230℃(分解)。以乙醇为原料制得。为抗胆碱药,用于治疗胃及十二脂肠溃疡,亦可解痉。不良反应类似阿托品。

说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条